HIV/HCV No Co-Infection (NoCo) 2019 Program: Grant applications announced Grant applications announced
Through Medical Affairs, Gilead will support projects with research grants of up to $600,000 each, with an emphasis on achieving geographic distribution across the globe. This is for projects that seek to address pressing unmet patient needs, including improving screening and linking patients living with HCV and HIV co-infection, to HCV treatment.
Targeting the micro-elimination of HCV in HIV-infected individuals, or those at high-risk of HIV infection, is a positive step towards global elimination and presents a feasible, short-term goal.
The NoCo program aims to support the research efforts of academic institutions, clinical investigators, community organisations and research networks, to help educate the scientific community on barriers and ways to facilitate HCV elimination.
The program will accept applications from around the world for projects that seek to address pressing unmet patient needs, including improving screening and linkage to care.
Successful proposals will demonstrate clear scientific objectives, defined timelines, a comprehensive operational plan and the potential to generate data that has relevance to the medical community and policy makers.
Additional information about the NoCo Program is found at Gilead.com
“Gilead is proud to support investigator-sponsored research areas across liver diseases, which we believe can help broaden understanding of how to manage these diseases and help patients be appropriately linked to care.”
– Bill Guyer, Senior Vice President, Head of Medical Affairs, Gilead Sciences
Key Dates & Program Specifics:
- Applications will be accepted from May 1 to June 14, 2019.
- Additional information about the NoCo Program will be announced shortly.
Questions about the program or application process should be submitted to your local Gilead Medical Scientist or to NoCo@gilead.com.